This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.
A randomized, placebo controlled study. Using a GIP receptor antagonist, we will investigate the glucose lowering effect of GIP during treatment with DPP-4 inhibitors.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
12
Saline infusion
Used for infusion on study days
Oral administration of DPP-4 inhibitor in active treatment period
Center for Clinical Metabolic Research
Copenhagen, Hellerup, Denmark
C-peptide
Concentrations of C-peptide during GIP receptor antagonism compared to placebo
Time frame: 5 hours
Plasma glucose
Concentrations of plasma glucose during GIP receptor antagonism compared to placebo
Time frame: 5 hours
Insulin
Concentrations of insulin during GIP receptor antagonism compared to placebo
Time frame: 5 hours
Total and intact GIP
Concentrations of total and intact GIP during GIP receptor antagonism compared to placebo
Time frame: 5 hours
Total and intact GLP-1
Concentrations of total and intact GLP-1 during GIP receptor antagonism compared to placebo
Time frame: 5 hours
Glucagon
Concentrations of glucagon during GIP receptor antagonism compared to placebo
Time frame: 5 hours
CTX
Concentrations of CTX during GIP receptor antagonism compared to placebo
Time frame: 5 hours
Lipids
Concentrations of lipids during GIP receptor antagonism compared to placebo
Time frame: 5 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Oral administration of placebo tablet in placebo treatment period